Lymphotoxin-LIGHT pathway regulates the interferon signature in rheumatoid arthritis.
Ontology highlight
ABSTRACT: A subset of patients with autoimmune diseases including rheumatoid arthritis (RA) and lupus appear to be exposed continually to interferon (IFN) as evidenced by elevated expression of IFN induced genes in blood cells. In lupus, detection of endogenous chromatin complexes by the innate sensing machinery is the suspected driver for the IFN, but the actual mechanisms remain unknown in all of these diseases. We investigated in two randomized clinical trials the effects on RA patients of baminercept, a lymphotoxin-beta receptor-immunoglobulin fusion protein that blocks the lymphotoxin-αβ/LIGHT axis. Administration of baminercept led to a reduced RNA IFN signature in the blood of patients with elevated baseline signatures. Both RA and SLE patients with a high IFN signature were lymphopenic and l
SUBMITTER: Bienkowska J
PROVIDER: S-EPMC4236099 | biostudies-literature | 2014
REPOSITORIES: biostudies-literature
ACCESS DATA